Literature DB >> 1645242

Chemotherapy for non-small cell lung cancer. The continuing challenge.

E E Vokes, J D Bitran, N J Vogelzang.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 1645242     DOI： 10.1378/chest.99.6.1326

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  A phase II trial of docetaxel and ifosfamide for patients with platinum-resistant or refractory non-small cell lung cancer in a salvage setting.

Authors:  Gyeong-Won Lee; Jung-Hun Kang; Seok-Hyun Kim; Hea Yong Lee; Ho-Cheol Kim; Won-Sup Lee; Jong-Duk Lee; Young-Sil Hwang; Joung-Soon Jang; Jong-Seok Lee
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

2.  Combination of gemcitabine and cisplatin as first-line therapy in advanced non-small-cell lung cancer.

Authors:  Nam-Su Lee; Jae-Ho Byun; Sang-Byung Bae; Chan-Kyu Kim; Kyu-Taeg Lee; Sung-Kyu Park; Jong-Ho Won; Dae-Sik Hong; Hee-Sook Park
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

3.  Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.

Authors:  Nam-Su Lee; Hee-Sook Park; Jong-Ho Won; Dae-Sik Hong; Su-Taek Uh; Sang-Jae Lee; Joo-Hang Kim; Se-Kyu Kim; Myung-Ju Ahn; Jung-Hye Choi; Suk-Chul Yang; Jung-Ae Lee; Keun-Seok Lee; Chang-Yeol Yim; Yong-Chul Lee; Chul-Soo Kim; Moon-Hee Lee; Kab-Do Jung; Hanlim Moon; Yl-Sub Lee
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

Review 4.  Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer.

Authors:  Yanni Hu; Mei Tian; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.